The mechanism of action and chemical synthesis of FDA newly approved drug molecules
Dan‐Dan Shen,Yue‐Lin Zhang,Xiang Li,Yi‐Ru Bai,Jun‐Feng Xiong,Dong‐Jie Seng,Yao‐Dong Zhang,Hong‐Min Liu,Shuo Yuan,Li Yang
DOI: https://doi.org/10.1002/ddr.22260
2024-09-11
Drug Development Research
Abstract:In 2023, the U.S. Food and Drug Administration has approved 29 small molecule drugs. These newly approved small molecule drugs possess the distinct scaffolds, thereby exhibiting diverse mechanisms of action and binding modalities. Moreover, the marketed drugs have always been an important source of new drug development and creative inspiration, thereby fostering analogous endeavors in drug discovery that potentially extend to the diverse clinical indications. Therefore, conducting a comprehensive evaluation of drug approval experience and associated information will facilitate the expedited identification of highly potent drug molecules. In this review, we comprehensively summarized the relevant information regarding the clinical applications, mechanisms of action and chemical synthesis of 29 small molecule drugs, with the aim of providing a promising structural basis and design inspiration for pharmaceutical chemists.
pharmacology & pharmacy,chemistry, medicinal